FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to the production of antagomirs to miRNA, and can be used in medicine for the treatment of vascular disease selected from the group consisting of peripheral vascular occlusive disease, coronary heart disease, cerebrovascular disease, vasculitis, atherosclerosis, vascular remodeling in response to injury or restenosis. Pharmaceutical composition with antagomir molecule miRNA-100 is prepared for the positive modulation of the growth of blood vessels, in this regard, for use in modulating the proliferation, tube formation and sprouting activities on endothelial cells or modulation of adhesion molecule expression by these cells.
EFFECT: invention improves the effectiveness of angiogenic therapy.
7 cl, 17 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR | 2014 |
|
RU2668794C2 |
| MIR-155 INHIBITORS FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL) | 2016 |
|
RU2718534C2 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| COMPOSITIONS AND METHODS FOR TREATING HAEMOGLOBINOPATHIES | 2015 |
|
RU2707540C2 |
| MIR-29 MIMETICS AND WAYS OF USE THEREOF | 2015 |
|
RU2712511C2 |
| VERSIONS OF RECOMBINANT AAV AND USE THEREOF | 2015 |
|
RU2738421C2 |
| METHODS OF TREATING POLYCYSTIC KIDNEY DISEASE | 2016 |
|
RU2742300C2 |
| OLIGODENDROCYTE-SPECIFIC PROMOTOR, microRNA SPECIFIC TO PLP1 GENE, VECTOR CONTAINING SPECIFIED PROMOTOR AND/OR SPECIFIED microRNA, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED VECTOR | 2019 |
|
RU2788605C2 |
